- Home
- BDC vs AXSM Comparison
BDC vs AXSM Comparison
Compare BDC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDC
- AXSM
- Stock Information
- Founded
- BDC 1902
- AXSM 2012
- Country
- BDC United States
- AXSM United States
- Employees
- BDC N/A
- AXSM N/A
- Industry
- BDC Telecommunications Equipment
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- BDC Telecommunications
- AXSM Health Care
- Exchange
- BDC Nasdaq
- AXSM Nasdaq
- Market Cap
- BDC 4.7B
- AXSM 5.1B
- IPO Year
- BDC 1993
- AXSM 2015
- Fundamental
- Price
- BDC $131.13
- AXSM $118.51
- Analyst Decision
- BDC Strong Buy
- AXSM Strong Buy
- Analyst Count
- BDC 5
- AXSM 16
- Target Price
- BDC $135.20
- AXSM $176.56
- AVG Volume (30 Days)
- BDC 321.9K
- AXSM 604.8K
- Earning Date
- BDC 07-31-2025
- AXSM 08-04-2025
- Dividend Yield
- BDC 0.15%
- AXSM N/A
- EPS Growth
- BDC 16.75
- AXSM N/A
- EPS
- BDC 5.50
- AXSM N/A
- Revenue
- BDC $2,617,821,000.00
- AXSM $495,033,000.00
- Revenue This Year
- BDC $8.98
- AXSM $61.62
- Revenue Next Year
- BDC $5.03
- AXSM $59.02
- P/E Ratio
- BDC $23.87
- AXSM N/A
- Revenue Growth
- BDC 12.93
- AXSM 69.83
- 52 Week Low
- BDC $83.18
- AXSM $75.56
- 52 Week High
- BDC $132.99
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- BDC 62.69
- AXSM 72.31
- Support Level
- BDC $122.39
- AXSM $102.67
- Resistance Level
- BDC $127.17
- AXSM $112.47
- Average True Range (ATR)
- BDC 3.28
- AXSM 3.25
- MACD
- BDC 0.47
- AXSM 1.55
- Stochastic Oscillator
- BDC 92.18
- AXSM 89.74
About BDC Belden Inc
Belden designs, manufactures, and markets advanced networking, connectivity, and cable solutions for industrial automation, smart buildings, and broadcast markets. Their portfolio includes cables, connectors, and networking equipment, enabling secure, reliable data transmission for applications in data centers, healthcare, education, hospitality, and more.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.